Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward

Be part of the knowledge.

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward

Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
This interview focuses on the role of EGFR and other molecular pathways in GBM pathophysiology, and will review latest clinical trial data.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Glioblastoma Multiforme (GBM) is the most common and most malignant of all glial tumors. These tumors present a challenge to the team managing the patient, as there is no curative treatment; the goal is to find the best approach and optimal role for each team member. There are a variety of treatment options, which include surgery (resection), radiotherapy, and chemotherapy. The prognosis for these patients is measured in years with respect to median survival; with one study reporting nearly 10% of patients live five years or longer. 

    The current clinical research environment includes a variety of new approaches to treating patients with GBM, and antibody-drug conjugates (ADCs) are one type of treatment currently being investigated. 

    In today's activity we will discuss the role of ADCs in managing patients with GBM.


  • Disclosure of Conflicts of Interest

    In accodance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    John Russell, MD
    Director Family Medicine Residency
    Abington Memorial Hospital
    Abington, PA
    Financial Disclosure:
    Commercial Interest Speakers Bureau: Sanofi Pasteur

    David A. Reardon, MD
    Professor of Medicine, Harvard Medical School
    Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute
    Boston, Massachusetts

    Faculty's disclosure: 

    Dr. Reardon receives research grants from Acerta Pharm, Celldex Therapeutics, EMD Serono,
    Incyte, Inovio, Midatech, and Tragara.  He holds an advisory role at AbbVie, Agenus, Amgen, BMS, Cavion, Celldex, EMO Serono, Genentech/Roche, Inovio, Juno Pharmaceuticals, Merck, Midatech, Momenta Pharmaceuticals, Novartis, Novocure, Oxigene, Regeneron, and Stemline Therapeutics.  He received honoraria from AbbVie, Agenus, Amgen, BMS, Cavion, Celldex, EMD Serono, Genentech/Roche, lnovio, Juno Pharmaceuticals, Merck, Midatech, Momenta Pharmaceuticals, Novartis, Novocure, Oxigene, Regeneron, and Stemline Therapeutics.  He is part of the speaker bureau for BMS, Merck, and Genentech/Roche. 


    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian McDonough, MD, FAAFP has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • Lawrence Sherman, FACEHP, CHCP has nothing to disclose.


  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the role of EGFR amplifications and other molecular aberrations in the underlying pathology of GBMs and their role in mediating resistance to current standard-of-care therapy
    • Evaluate evidence from clinical trials on the effectiveness and safety of novel targeted treatments for GBMs, including antibody-drug conjugates and determine their place in current GBM treatment paradigms.


  • Target Audience

    This activity is designed to meet the educational needs of clinicians who manage patients with glioblastoma including:

    • Medical Oncologists
    • Surgical Oncologist
    • Radiation Oncologists
    • Oncology Nurses
    • Pharmacists
    • Other HCPs managing patients with glioblastoma
  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

  • Provider

    TOPEC Global LLC (GmbH) is an independent medical health education provider based in Sachseln, Switzerland. We are expert at designing, developing, delivering, and measuring the impact of education across a broad spectrum of diseases and clincal conditions. Our mission is to assist healthcare professionals in their pursuit of continuous professional development through an array of integreated, lifelong learning opportunities that lead to improvements in competence, performance, and patient outcomes. 


  • Commercial Support

    This activity is supported by an independent educational grant from AbbVie Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the view of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patietn management; the participant should use his/her clinical judgement, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia/Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.